Set to streamline and speed products to market while reducing cost and complexity of development
Bespak, a UK-based drug delivery device developer and contract development and manufacturing organisation (CDMO) Aesica, are providing a single source supply chain solution for drug delivery products incorporating formulation development, device design and development, drug and device manufacture, fill/finish and secondary packaging. This has been made possible following Consort Medical’s acquisition of Aesica in September 2014.
Consort Medical has combined Aesica’s drug formulation, manufacturing and packaging capabilities with Bespak’s drug delivery device, design, development and manufacturing services. The full range of services now provided by the firms includes inhalation, nasal, ocular, Buccal, and transdermal drug delivery device concept generation, design, development, and manufacture at pilot through to high volume commercial scale, as well as API and formulation development and manufacture and finished dose fill/finish.
The two sister companies have strong synergies and similarities across quality control, regulatory compliance and reliable manufacturing. This includes QP release and ISO certified Quality Management Systems, cGMP compliance and operating to FDA and MHRA standards of approval. Both companies also comply with environmental and health and safety standards. Aesica provides secure facilities that handle up to schedule 2 controlled substances, together with a high containment suite capable of manufacturing products in the SafeBridge category 3 potency level.
Both brands provide pilot up to volume manufacturing – operating at scales from low volume pilot manufacture to very high volume automated production operations and from grams to full scale manufacture of drugs.